Literature DB >> 18684125

A survey of adherence to haemophilia therapy in six European countries: results and recommendations.

P De Moerloose1, W Urbancik, H M Van Den Berg, M Richards.   

Abstract

Very few studies have addressed the question of adherence of haemophiliacs to their treatment. The aim of our study was to compare their levels of adherence to therapy and also to provide recommendations. Professionals of an international research company performed individual interviews with 30 patients in each of six European countries (France, Germany, Italy, Spain, Sweden and UK) resulting in a total of 180 patients. Twenty-eight interviews with haemophilia physicians and specialist nurses were also undertaken. Overall adherence to treatment was high (80-87% in each country). There was a positive correlation between greater adherence and younger age, prophylactic treatment, time spent with a haemophilia treatment centre (HTC) and the quality of the relationship with the haematologist and nurse. The four leading reasons for not using the prescribed amount of clotting factor or skipping the administration interval were reduction, fluctuation or disappearance of symptoms, forgetfulness, lack of time for treatment and convenience. These reasons differed according to the country and the age of the patient. The main suggestions made by patients to improve adherence related to HTC, environment and factor concentrates. Patients considered also that internet and electronic patient diaries were likely to improve adherence. In this selected group of European haemophilia patients, adherence to treatment appears higher than for most patients with other chronic diseases. However, it remains important to be aware of the possibility of non-adherence given the serious implications, particularly when considering a differently selected group of patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18684125     DOI: 10.1111/j.1365-2516.2008.01843.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  43 in total

1.  Prophylaxis for adults with haemophilia: one size does not fit all.

Authors:  Kathelijn Fischer
Journal:  Blood Transfus       Date:  2012-04       Impact factor: 3.443

2.  Treatment-related knowledge and skills of patients with haemophilia and their informal caregivers.

Authors:  Teddy Novais; Antoine Duclos; Remi Varin; Isabelle Lopez; Valérie Chamouard
Journal:  Int J Clin Pharm       Date:  2016-02

3.  Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE Study.

Authors:  Ezio Zanon; Annarita Tagliaferri; Samantha Pasca; Cosimo P Ettorre; Lucia D Notarangelo; Chiara Biasioli; Anna B Aru; Marta Milan; Silvia Linari; Angiola Rocino; Fabio Gagliano; Giovanni Di Minno; Gabriella Gamba; Rita C Santoro; Piercarla Schinco; Marco Marietta; Axel Seuser; Sylvia von Mackensen
Journal:  Blood Transfus       Date:  2019-06-05       Impact factor: 3.443

4.  Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal?

Authors:  Ingrid den Uijl; Douwe Biesma; Diederick Grobbee; Kathelijn Fischer
Journal:  Blood Transfus       Date:  2012-11-06       Impact factor: 3.443

5.  Health care resource utilization and cost burden of hemophilia B in the United States.

Authors:  Tyler W Buckner; Iryna Bocharova; Kaitlin Hagan; Arielle G Bensimon; Hongbo Yang; Eric Q Wu; Eileen K Sawyer; Nanxin Li
Journal:  Blood Adv       Date:  2021-04-13

6.  Infected tooth extraction, bone grafting, immediate implant placement and immediate temporary crown insertion in a patient with severe type-B hemophilia.

Authors:  Jose Luis Calvo-Guirado; Georgios E Romanos; Rafael Arcesio Delgado-Ruiz
Journal:  BMJ Case Rep       Date:  2019-03-22

7.  Recombinant factor VIII in the management of hemophilia A: current use and future promise.

Authors:  Jerry S Powell
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

8.  Design and Usability of an Electronic Health Record-Integrated, Point-of-Care, Clinical Decision Support Tool for Modeling and Simulation of Antihemophilic Factors.

Authors:  Susan M Abdel-Rahman; Harpreet Gill; Shannon L Carpenter; Pathe Gueye; Brian Wicklund; Matt Breitkreutz; Arindam Ghosh; Avinash Kollu
Journal:  Appl Clin Inform       Date:  2020-04-08       Impact factor: 2.342

9.  Physician trust and depression influence adherence to factor replacement: a single-centre cross-sectional study.

Authors:  D Q Tran; V Barry; A Antun; M Ribeiro; S Stein; C L Kempton
Journal:  Haemophilia       Date:  2016-09-30       Impact factor: 4.287

10.  Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.

Authors:  Johnny Mahlangu; Kazimierz Kuliczkowski; Faraizah Abdul Karim; Oleksandra Stasyshyn; Marina V Kosinova; Lynda Mae Lepatan; Aleksander Skotnicki; Lisa N Boggio; Robert Klamroth; Johannes Oldenburg; Andrzej Hellmann; Elena Santagostino; Ross I Baker; Kathelijn Fischer; Joan C Gill; Stephanie P'Ng; Pratima Chowdary; Miguel A Escobar; Claudia Djambas Khayat; Luminita Rusen; Debra Bensen-Kennedy; Nicole Blackman; Tharin Limsakun; Alex Veldman; Katie St Ledger; Ingrid Pabinger
Journal:  Blood       Date:  2016-06-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.